Breast cancer-specific mortality (BCSM) in patients age 50 years or younger with node-positive (N plus ) breast cancer (BC) treated based on the 21-gene assay in clinical practice

Introduction: The 21-gene Breast Recurrence Score® assay was shown in SWOG 8814 to predict chemotherapy (CT) benefit for patients (pts) with N+ BC and Recurrence Score® (RS) result≥31 but not RS Citation Format: Valentina I Petkov, Allison W Kurian, Debbie M Jakubowski, Steven Shak. Breast cancer-specific mortality (BCSM) in patients age 50 years or younger with node-positive (N+) breast cancer (BC) treated based on the 21-gene assay in clinical practice [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-07-01.